We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current NTLA market cap is 2.35B. The company's latest EPS is USD -5.0069 and P/E is -4.71.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 13.27M | 13.57M | 12.61M | 13.59M | 11.99M |
| Operating Income | -107.36M | -113.34M | -115.01M | -136.33M | -134.96M |
| Net Income | -113.23M | -113.41M | -103.13M | -123.68M | -122.22M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 43.1M | 57.99M | 33.05M | 52.12M | 36.28M |
| Operating Income | -106.37M | -136.58M | -269.18M | -469.24M | -530.92M |
| Net Income | -99.53M | -134.23M | -267.89M | -474.19M | -481.19M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.08B | 1.52B | 1.42B | 1.32B | 1.24B |
| Total Liabilities | 259.51M | 284.53M | 227.05M | 218.35M | 205.94M |
| Total Equity | 824.95M | 1.24B | 1.19B | 1.1B | 1.04B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 334.28M | 676.32M | 1.29B | 1.52B | 1.3B |
| Total Liabilities | 64.4M | 149.25M | 254.22M | 284.53M | 250.81M |
| Total Equity | 269.88M | 527.07M | 1.04B | 1.24B | 1.05B |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -243.42M | -333.29M | -109.33M | -199.65M | -301.03M |
| Investing | 190.46M | 160.31M | -122.25M | -156.79M | -77.29M |
| Financing | 77.19M | 582.96M | 2.22M | 4.74M | 23.84M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -103.24M | -49.91M | -225.03M | -333.29M | -394.09M |
| Investing | 25.18M | -214.49M | -550.78M | 160.31M | -31.35M |
| Financing | 76.43M | 371.78M | 736.69M | 582.96M | 130.32M |
| Market Cap | 2.35B |
| Price to Earnings Ratio | -4.71 |
| Price to Sales Ratio | 62.48 |
| Price to Cash Ratio | 9.99 |
| Price to Book Ratio | 2.16 |
| Dividend Yield | - |
| Shares Outstanding | 96.11M |
| Average Volume (1 week) | 1.29M |
| Average Volume (1 Month) | 1.22M |
| 52 Week Change | -34.06% |
| 52 Week High | 47.48 |
| 52 Week Low | 19.37 |
| Spread (Intraday) | 24.07 (83.09%) |
| Company Name | Intellia Therapeutics Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.intelliatx.com |
| Industry | in vitro,in vivo diagnostics (2835) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
